

Inclusion Criteria:

Previously healthy children aged 6 months to 6 years with signs and symptoms of viral illness with associated barky cough and inspiratory stridor

Exclusion Criteria:

Alternative diagnosis should be considered if:

- Toxic Appearance: Pallor, lethargic, acute/abrupt onset and unimmunized status should prompt consideration for bacterial tracheitis / epiglottitis
- Drooling or difficulty swallowing (FB, retropharyngeal abscess)
- Expiratory wheezing
- Known previous history: Laryngo/ tracheomalacia, or previously diagnosed vascular ring/sling/ tracheoesophageal fistula
- Prior non-elective intubation in past 6 months, or prolonged intubation
- Recurrent episodes, two episodes in last 30 days, three episodes in 1 year.

Croup Severity Score				
Air Entry	Normal (0)	Decreased (1)	Markedly Decreased (2)	
Chest Wall Retractions	None (0)	Mild (1)	Moderate (2)	Severe (3)
Cyanosis	None (0)	With Agitation (4)	At Rest (5)	
Level of Consciousness	evel of Consciousness Normal (0) Disoriented (5)			
Stridor	None (0)	With Agitation (1)	At Rest (2)	

Generally, lab testing, viral testing, and X-Ray (chest and/or lateral neck) do not alter or change outcomes in typical croup

Reviewers:				
Created by	Department	Creation Date	Version Date	
H. Greening, J. McCarthy	PHM, PEM	09/2016	7/2023	



Croup

Mild Croup	Moderate Croup	Severe Croup	Impending Respiratory Failure		
Score < 2	Score 3 to 7	Score 8 to 11	Score >12		
	Single dose of PO/IM/IV dexamethasone 0.3-0.6mg/kg (MAXIMUM dose 16mg)				
*Multiple st	udies have shown mild croup can	be treated with lower dosing of	dexamethasone down to 0.15mg/kg.		
Education regarding	Minimize intervention/stress	Minimize intervention/stress	Minimize intervention/stress		
illness course, concerning symptoms and when to seek medical assessment.	Place child in position of comfort *	Place child in position of comfort* Give racemic epi neb (2.25% or 0.5ml in 2.5mL of saline).	Place child in position of comfort. * O2 via NC or mask should be administered. Hypoxemia is rare in croup and should be as a sign of impending respiratory failure . Give racemic epi neb (2.25% or 0.5ml in 2.5mL of saline). Consider IM epi, Heliox 70/30, or HFNC.		
Home treatment: Antipyretics, cool-mist, oral fluids	May consider trial of racemic epinephrine (2.25% or 0.5ml in 2.5mL of saline). If racemic epi given, minimum 3-hour observation	Repeated doses of nebulized racemic epinephrine may be needed	Nebulized racemic epinephrine repeated doses as needed.		
Discharge home with follow up in 24-48hrs	Hospitalization is generally not needed but may be warranted for persistent or worsening symptoms or if repeated doses of racemic epinephrine are needed.	Hospital admission is warranted If repeat racemic epi nebulizers are needed, oxygen requirement or stridor at rest.	Contact pediatric ICU or Anesthesiology for airway stabilization and for further management. Call for transfer to tertiary care facility. Update Pediatric ENT for assistance with further management.		

*Place child in parents lap during exam, minimize agitation and intervention including IV, blood draws, etc. Involve parents in placing exam, placing nasal cannula and in giving medications. Involve Child Life specialist for distractions if available

ED Discharge Criteria

- Receives 1 dose of dexamethasone
- ≥ 3 hours since last racemic epinephrine treatment (if received)
- ≤ 2 racemic epinephrine within 4 hours
- Mild or improved croup symptoms
 - Minimal/improved or no stridor refer to scoring
 - Minimal/improved or no suprasternal or intercostal retractions at rest refer to above scoring
- Able to talk and feed without difficulty
- No supplemental oxygen or hydration requirement

Inpatient Admission Considerations (does not substitute for clinical judgment)

- Receives ≥ 3 racemic epinephrine or requires racemic epinephrine more frequently than Q2 hours x 2 doses in the ED and/or
- Persistent stridor at rest, respiratory distress, tachypnea or
- Inadequate hydration or
- Need for supplemental oxygen or
- Concern for alternative diagnosis

Reviewers:				
Created by	Department	Creation Date	Version Date	
H. Greening, J. McCarthy	PHM, PEM	09/2016	7/2023	

https://www.advocatechildrenshospital.com/healthcare-professionals/peds-pathways



Croup

Does not exceed floor care limitations:

- Floor can administer racemic epinephrine Q2hours; Floor cannot start heliox or positive pressure ventilation.
- If a child is unable to go more than 2 hours between racemic epi nebs, needs hourly treatments/ assessments, or fails to respond to interventions, should consider ICU level of care.

Inpatient Clinical Recommendations

- There is no indication for cool mist humidified oxygen therapy for the hospital treatment of croup.
- Most children show rapid improvement with racemic epinephrine, failure to respond should prompt consideration of alternative diagnosis.
- Lab testing, viral testing, neck imaging does not alter the management of croup.
- No indication for home racemic epinephrine nebulizer treatments.
- No strong indication for repeat doses of steroids at time of discharge except croup associated with COVID-19. Those patients may need repeat dosing of steroids within 24-48 hours.

ENT Consultation Criteria

- ENT Inpatient Consultation for direct laryngoscopy/ bronchoscopy or bedside flexible laryngoscopy if history of intubation, recurrent episodes outside normal age range (< 6months, > 6 years), concern for airway anomalies, atopy or GERD.
- Consider consultation if fail to improve after 36hrs hours of receiving first steroid dose, racemic epinephrine and observation.

Inpatient Discharge Criteria:

- Minimal stridor at rest. No signs or symptoms of significant respiratory distress
- Adequate oral hydration
- Greater than 4-6 hours since last racemic epinephrine
- No oxygen requirement for several hours
- Appropriate follow up for the child in the outpatient setting

Reviewers:					
Created by	Department	Creation Date	Version Date		
H. Greening, J. McCarthy	PHM, PEM	09/2016	7/2023		



References:

- 1. Cherry JD. Clinical practice. Croup. N Engl J Med. 2008;358(4):384–391
- 2. Bjornson C.L., Johnson D.W.: Croup. Lancet 2008; 371:329-339.
- 3. Gates A, Gates M, Vandermeer B, Johnson C, Hartling L, Johnson DW, Klassen TP. Glucocorticoids for croup in children. Cochrane Database of Systematic Reviews 2018, Issue 8. Art. No.: CD001955. DOI: 10.1002/14651858.CD001955.pub4.
- 4. Johnson, DW. Croup. BMJ Clin Evid. 2009; 2009: 0321.
- 5. Kleigman, Behrman et al. Nelson's Textbook fo Pediatrics 18th Edition. Croup 1764-1772
- 6. Mazza D, Wilkinson F, Turner T, Harris C; Health for Kids Guideline Development Group. Evidence based guideline for the management of croup. Aust Fam Physician. 2008;37:14–20.
- 7. Moore M, Little P. Humidified air inhalation for treating croup. Cochrane Database Syst Rev. 2010;(9):CD002870.
- 8. Neto, G., et al., A randomized controlled trial of mist in the acute treatment of moderate croup. Acad Emerg Med, 2002. 9(9): 873-9.
- 9. Russell KF, Liang Y, O'Gorman K, et al. Glucocorticoids for croup. Cochrane Database Syst Rev 2011; CD001955.
- 10. Westley, C., C.E.K. Ross, and J.G. Brooks, Nebulized racemic epinephrine by IPPB for the treatment of croup. Am J Dis Child, 1978. 132(May): 484-487.
- 11. Woods, C. R. et al. Croup: Approach to management. Up-to-date last updated April 17, 2015.
- 12. Toward Optimized Practice. Guideline for the diagnosis and management of croup. 2008 update. http://www.topalbertadoctors.org/informed_practice/clinical_practice_guidelines/complete%20set/Croup/croup_pda.pdf.
- 13. 12. Fifoot AA, Ting JY. Comparison between single-dose oral prednisolone and oral dexamethasone in the treatment of croup: a randomized, double-blinded clinical trial. Emerg Med Australas. 2007;19(1):51-58. doi:10.1111/j.1742-6723.2006.
- 14. Chub-Uppakarn S, Sangsupawanich P. A randomized comparison of dexamethasone 0.15 mg/kg versus 0.6 mg/kg for the treatment of moderate to severe croup. Int J Pediatr Otorhinolaryngol. 2007;71(3):473-477. doi:10.1016/j.ijporl.2006.11.016Đ
- 15. Venn AMR, Schmidt JM, Mullan PC. Pediatric croup with COVID-19. Am. J. Emerg. Med. 2021; 43: e1–3.
- 16. 5. Pitstick CE, Rodriguez KM, Smith AC, Herman HK, Hays JF, Nash CB. A curious case of croup: Laryngotracheitis caused by COVID-19. *Pediatrics* 2021; 147: e2020012179.
- 17. Croup Clinical Pathways Referenced: Children's Hospital of Colorado, Phoenix Children's Hospital, Seattle Children's Hospital, Children's Hospital of Philadelphia
- 18. Nadine Smith, Kathryn Giordano, Amy Thompson, and Andrew DePiero Failure of Outpatient Management With Different Observation Times After Racemic Epinephrine for Croup, Clinical Pediatrics 2017 57:6, 706-710
- 19. Pitluk, J.D., H. Uman, and S. Safranek, Clinical inquiries. What's best for croup? J Fam Pract, 2011. 60(11): p. 680-1. 13.
- 20. Bjornson, C., et al., Nebulized epinephrine for croup in children. Cochrane Database Syst Rev, 2013(10): p. Cd006619.
- 21. Maalouli, W.M. and J.S. Hodges, Croup Admissions: Can We Shrink the Elephant in the Room? Pediatr Emerg Care, 2019.
- 22. Asmundsson, A.S., et al., Hospital Course of Croup After Emergency Department Management. Hosp Pediatr, 2019. 9(5): p. 326-332.
- 23. Bagwell, T., et al., Management of Croup in the Emergency Department: The Role of Multidose Nebulized Epinephrine. Pediatr Emerg Care, 2017.
- Elder, A.E. and A. Rao, Management and outcomes of patients presenting to the emergency department with croup: Can we identify which patients can safely be discharged from the emergency department? J Paediatr Child Health, 2019. 55(11): p. 1323-1328.
- 25. Chiang, E., et al., Inpatient use of racemic epinephrine for children admitted with croup. World J Pediatr, 2019. 15(6): p. 586-594

Reviewers:				
Created by	Department	Creation Date	Version Date	
H. Greening, J. McCarthy	PHM, PEM	09/2016	7/2023	

https://www.advocatechildrenshospital.com/healthcare-professionals/peds-pathways